Exelixis' Cotellic Fails To IMblaze A Trail In Colorectal Cancer
Executive Summary
The failure of a Cotellic/Tecentriq combo in the IMblaze370 trial highlights Exelixis' dependence on its renal cell carcinoma drug CaboMetyx and the treatment challenges of the aggressive and difficult-to-treat disease that is metastatic colorectal cancer.
You may also be interested in...
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Roche’s Tecentriq IMpower150 trial showed Tecentriq plus Avastin plus paclitaxel and carboplatin significantly improved progression free survival compared to Avastin and chemo alone; overall survival data will be coming later this year.
CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC
The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.